Scarica l'app Stockscreener
15.50
2.15%
-0.34
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GLUE Giù?
Forum
Previsione
Monte Rosa Therapeutics Inc Borsa (GLUE) Ultime notizie
Widening Losses And Profitability Swing Might Change The Case For Investing In Monte Rosa Therapeutics (GLUE) - simplywall.st
Monte Rosa Therapeutics (GLUE) holders report sub‑5% stakes in amended 13G - Stock Titan
Monte Rosa Therapeutics (GLUE): Vestal Point discloses 4.6M-share, 5.4% ownership - Stock Titan
GLUE|Monte Rosa Therapeutics Inc|Price:15.500|Chg%:-0.340 - TradingKey
Industry Analysts Just Upgraded Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Revenue Forecasts By 21% - webull.com
Why Monte Rosa Therapeutics (GLUE) Is Back In Focus After Its Latest Update - Sahm
Analysts Are Upgrading Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) After Its Latest Results - webull.com
What Monte Rosa Therapeutics (GLUE)'s Swing From Profit To Deeper Losses Means For Shareholders - simplywall.st
Monte Rosa Therapeutics (NASDAQ:GLUE) Announces Earnings Results - MarketBeat
MONTE ROSA THERAPEUTICS, INC. : WELLS FARGO CUTS TARGET PRICE TO $27 FROM $29 - webull.com
Monte Rosa Therapeutics, Inc. (GLUE) stock price, news, quote and history - Yahoo Finance Singapore
The Manufacturers Life Insurance Company Raises Stake in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Dimensional Fund Advisors LP Acquires 473,005 Shares of Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
JPMorgan Chase & Co. Has Lowered Expectations for Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price - MarketBeat
Wells Fargo & Company Lowers Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target to $27.00 - MarketBeat
Monte Rosa Therapeutics Is Maintained at Overweight by Wells Fargo - Moomoo
LifeSci Capital Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating - Moomoo
Monte Rosa Therapeutics (GLUE) Is Down 30.7% After Deepening Q2 Losses And H1 Earnings Reversal - Yahoo Finance
Monte Rosa Therapeutics earnings missed by $0.05, revenue fell short of estimates - Investing.com Canada
(GLUE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Monte Rosa Therapeutics, Inc. Stock 12‑Month Price Target Cut to $30.33, Implies 94% Upside - TradingView
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Zacks Research Upgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to "Hold" - MarketBeat
Monte Rosa Therapeutics: Q2 Earnings Snapshot - AOL.com
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D - TradingView
Monte Rosa posts $43.4 million Q2 loss as pipeline trials advance - Quiver Quantitative
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - The Manila Times
Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q2 Collaboration Revenue $9.0M, Vs. FactSet Est of $12.9M - Moomoo
Monte Rosa Therapeutics reports Q2 2026 net loss $43.4M, cash position $626.0M supporting operations into 2029 - TradingView
Monte Rosa Therapeutics Q2 2026: Revenue $9M, EPS $(0.43) — 10-Q Summary - TradingView
Monte Rosa Therapeutics (NASDAQ: GLUE) posts 2026 net loss on revenue drop - Stock Titan
BRIEF-Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million - TradingView
Press Release: Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - Moomoo
Monte Rosa Q2 2026 earnings: Higher R&D widens loss as pipeline advances - TradingKey
Monte Rosa earnings on deck as cardiovascular data looms By Investing.com - Investing.com India
Monte Rosa Eyes Key Pipeline Readouts; Wedbush Analyst Reiterates Outperform Rating - RTTNews
Janus Henderson Group PLC Invests $11.29 Million in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Renaissance Technologies LLC Makes New Investment in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target Lowered to $27.00 at Wedbush - MarketBeat
Monte Rosa Therapeutics (GLUE) Plunges 27%: Critical Support Test After Steep SelloffConversion Trade - dars.gov.et
Arrowstreet Capital Limited Partnership Acquires 340,088 Shares of Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Why is Monte Rosa Therapeutics stock plunging today? By Investing.com - Investing.com Canada
Monte Rosa, BioAge plunge as Novo’s setback casts a shadow over pipeline - Seeking Alpha
Monte Rosa Therapeutics (GLUE) to Release Earnings on Thursday - MarketBeat
Monte Rosa Therapeutics Inc - TradingKey
Analysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), Atea Pharmaceuticals (AVIR) - The Globe and Mail
Exome Asset Management LLC Takes $2.95 Million Position in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics Inc (GLUE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Monte Rosa Therapeutics Inc (GLUE) Cash Flow - TradingKey
Monte Rosa Therapeutics Inc (GLUE) Income Statement - TradingKey
Monte Rosa Therapeutics, Inc. Revenue Breakdown – BOATS:GLUE - TradingView
Monte Rosa Therapeutics Inc (GLUE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Monte Rosa Therapeutics Inc (GLUE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Monte Rosa Therapeutics Inc (GLUE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
GLUE|Monte Rosa Therapeutics Inc|Price:22.780|Chg%:-0.250 - TradingKey
Price to sales forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Monte Rosa Therapeutics Market Sentiment - Benzinga España
Price to sales forward of Monte Rosa Therapeutics, Inc. – BOATS:GLUE - TradingView
Allspring Global Investments Holdings LLC Buys 365,272 Shares of Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight - The Manila Times
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight - GlobeNewswire Inc.
Enterprise value to EBITDA forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Have Insiders Sold Monte Rosa Therapeutics Shares Recently? - simplywall.st
Enterprise value to revenue forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Price to earnings forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):